Assessing health state utilities for people with myalgic encephalomyelitis/chronic fatigue syndrome in Australia using the EQ-5D-5L, AQoL-8D and EQ-5D-5L-psychosocial instruments. — CFSMEATLAS
Assessing health state utilities for people with myalgic encephalomyelitis/chronic fatigue syndrome in Australia using the EQ-5D-5L, AQoL-8D and EQ-5D-5L-psychosocial instruments.
Orji, Nneka C, Cox, Ingrid A, Jason, Leonard A et al. · Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024 · DOI
Quick Summary
This study measured how much ME/CFS affects quality of life in 198 Australian people with the condition. Researchers used three different questionnaires to assess health-related quality of life and found that people with ME/CFS reported significantly lower quality of life scores compared to healthy people. As people's fatigue and disability became more severe, their quality of life scores dropped further.
Why It Matters
This research quantifies the profound impact ME/CFS has on quality of life, providing critical data for healthcare planning, policy-making, and clinical trial design. Identifying which measurement tools best capture ME/CFS-related quality of life changes improves future research precision and ensures patients' experiences are accurately reflected in medical assessments.
Observed Findings
Mean health state utility scores for people with ME/CFS were 0.46 (EQ-5D-5L), 0.43 (AQoL-8D), and 0.44 (EQ-5D-5L-Psychosocial)—substantially lower than general population norms of 0.89 and 0.77.
All three instruments showed consistent inverse relationships between increasing disability/fatigue severity and health state utility scores.
AQoL-8D and EQ-5D-5L-Psychosocial demonstrated interchangeability according to Bland-Altman analysis.
Only the EQ-5D-5L showed floor effects (13.5% of respondents), suggesting limitations in capturing the lower end of quality of life for some patients.
Inferred Conclusions
ME/CFS causes a profound, measurable reduction in health-related quality of life substantially worse than the general population.
The AQoL-8D and EQ-5D-5L-Psychosocial are effectively interchangeable tools for measuring ME/CFS-related quality of life, with the latter preferred due to reduced respondent burden.
The EQ-5D-5L alone may not adequately capture all dimensions of quality of life impairment in ME/CFS patients due to floor effects.
Remaining Questions
How does quality of life change over time in ME/CFS patients—do these utility scores remain stable or decline progressively?
Do these findings generalize to ME/CFS populations outside Australia, including different healthcare and social support contexts?
What This Study Does Not Prove
This study does not prove that any particular treatment improves quality of life, nor does it establish causal relationships between specific ME/CFS symptoms and quality of life outcomes. As a cross-sectional survey, it captures a single point in time and cannot demonstrate how quality of life changes over the disease course. The results apply specifically to the Australian population and may not generalize to other countries or demographics.
Tags
Symptom:Fatigue
Method Flag:Weak Case DefinitionNo ControlsSmall Sample
Which specific dimensions of health-related quality of life (physical, psychological, social) contribute most to the observed utility deficits, and are these dimensions equally affected across severity levels?
Could these utility scores be used to evaluate the cost-effectiveness of future ME/CFS treatments, and what improvement thresholds would be clinically meaningful?